ArticleFrontiers in immunology2026
ZC3H15 in human tumors: a pan-cancer exploration of its clinical significance, molecular function, and association with the tumor immune microenvironment.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zinc finger CCCH-type protein 15 (ZC3H15) is a ribosome-associated eukaryotic protein involved in many biological processes, including gene expression regulation, translation, and immune modulation. Although ZC3H15 has been implicated in the development of certain tumors, its expression, functional relevance, diagnostic potential, and prognostic value in a pan-cancer context remain not fully elucidated. This study conducts an integrative, systematic, and comparative analysis of ZC3H15 across 33 cancer types and subsequently provides further experimental validation in liver cancer. Methods: mRNA expression data of ZC3H15 were obtained from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) datasets. Protein level validations were performed using the Human Protein Atlas (HPA) database and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) database. The cBioPortal database was used to analyze the genomic alteration of ZC3H15. Two pathway enrichment analysis methods were conducted to explore the biological functions and molecular mechanisms of ZC3H15 in pan-cancer. Results: The results indicated that ZC3H15 was overexpressed in a wide range of tumors. In certain cancers, particularly LIHC, LUAD, BRCA, LUSC, and HNSC, its expression was significantly correlated with poor patient prognosis. Mutations and amplifications were the most common gene alterations in ZC3H15. The GSCA database showed that methylation levels were reduced in most tumor types. Abnormal expression of ZC3H15 was related to immune cell infiltration. Gene enrichment analysis indicated that ZC3H15-related genes involved in tumor progression were significantly enriched in multiple cell cycle processes. We demonstrated that knockdown of ZC3H15 suppressed cell proliferation, migration, and invasion in two liver cancer cell lines, MHCC97H and Huh7, and two BRCA cell lines, MDA-MB-231 and Hs 578T. To further clarify the functional mechanism, subsequent immunofluorescence staining confirmed that ZC3H15 knockdown induced prometaphase arrest in MHCC97H and Huh7 liver cancer cells. Conclusions: Overall, this pan-cancer study demonstrates that ZC3H15 serves as a potential biomarker for cancer diagnosis, prognosis, and immune cell infiltration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.